CN Patent

CN115677830A — 肽酰胺类化合物及其制备方法与应用

Assigned to Tiandi Hengyi Pharmaceutical Co ltd · Expires 2023-02-03 · 3y expired

What this patent protects

本发明公开了一种肽酰胺类化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐或共晶，其具有所示(Ⅰ)结构通式： 该肽酰胺类化合物作为K阿片样受体激动剂具有活性更好、副作用更小、成药性更好的优点。

USPTO Abstract

本发明公开了一种肽酰胺类化合物或其立体异构体、水合物、代谢产物、溶剂化物、药学上可接受的盐或共晶，其具有所示(Ⅰ)结构通式： 该肽酰胺类化合物作为K阿片样受体激动剂具有活性更好、副作用更小、成药性更好的优点。

Drugs covered by this patent

Patent Metadata

Patent number
CN115677830A
Jurisdiction
CN
Classification
—
Expires
2023-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Tiandi Hengyi Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.